Return to Trial Database

BRE06-109

A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group Study BRE06-109

Status

Study Completed

Cancer Type(s)

Study Contact

Publications

A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer

Trial Locations

All sites in which the trial BRE06-109 being conducted in.

No data was found